Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Richard Adams, Ewan Brown, Louise Brown, Rachel Butler, Stephen Falk, David Fisher, Richard Kaplan, Phil Quirke, Susan Richman, Leslie Samuel, Jenny Seligman, Matt Seymour, Kai Keen Shui, Harpreet Wasan, Richard Wilson, Tim Maughan

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)
11 Downloads (Pure)
Original languageEnglish
Pages (from-to)162–171
Number of pages9
JournalThe Lancet Gastroenterology & Hepatology
Issue number3
Early online date15 Dec 2017
Publication statusPublished - Mar 2018

Bibliographical note

This study was funded by the UK Medical Research Council (MRC)
and National Institute for Health Research (NIHR) Efficacy and
Mechanism Evaluation programme; Cancer Research UK; NIHR
Clinical Trials Research Network; Health and Care Research Wales
(and equivalent in devolved nations); and AstraZeneca Drug Supply
and Distribution. PQ, MS, and SR received programme grant
support from Yorkshire Cancer Research. PQ is an NIHR Senior
Investigator at the Department of Pathology Cardiff and Vale
University Health Board, All Wales Genetics Laboratories, Wales
Cancer Bank. The MRC Clinical Trials Unit at University College
London receives funding from the MRC (programme grant


  • colorectal cancer
  • biomarkers
  • therapeutic efficacy
  • EGFR inhibitors

Cite this